Taiwan biotech firm ScienCell showcases CNS drug YA-101, seeks overseas partners

Taiwanese biotech firm ScienCell is presenting its flagship drug candidate, YA-101, at the Asian Bio-Congress and Exhibition. The company is focused on developing novel treatments for central nervous system disorders, with YA-101 primarily targeting Multiple System Atrophy (MSA). Currently in Phase II clinical trials across multiple international sites, ScienCell is actively seeking global partners to accelerate the drug's development and potential market entry. The company aims to establish YA-101 as a first-in-class treatment for MSA patients.

YA-101 has garnered significant regulatory attention, receiving Fast Track designation from the U.S. Food and Drug Administration (FDA). Furthermore, it has been granted orphan drug status in the United States, Japan, and the European Union. These designations are expected to expedite the FDA review process and could grant ScienCell up to seven years of market exclusivity in the U.S. post-approval, along with extended re-examination periods in Japan, bolstering the drug's future commercial prospects.

“

YA-101 has received the U.S. Food and Drug Administration's (FDA) New Drug 'Fast Track Designation' and was granted orphan drug status in the United States, Japan, and the European Union.

Beyond its work on MSA, ScienCell's innovative pipeline includes preclinical research for Alzheimer's disease and schizophrenia. The company's AI-driven new drug for neurodegenerative diseases was also selected for an international joint clinical trial program, positioning it as a priority drug for Parkinson's research. This inclusion could lead to further clinical trials funded by the UK's Cure Parkinson's charity. ScienCell hopes its participation in the exhibition will foster collaborations for global clinical development, registration, and commercialization of its central nervous system therapies.

“

Currently, YA-101 is undergoing Phase II clinical trials for treating patients with multiple system atrophy. The trials are proceeding smoothly across multiple clinical trial centers in the United States, Japan, and Taiwan, and international licensing efforts have already begun.